How to Get Mounjaro in Delaware

What Mounjaro Is and Why Delaware Clinicians Prescribe It

Tirzepatide (Mounjaro) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA granted approval for type 2 diabetes management in May 2022 [1]. The same molecule, at higher maintenance doses, was approved as Zepbound for chronic weight management in adults with a BMI <30 who have at least one weight-related comorbidity, or any adult with a BMI of 30 or above [2].

Delaware physicians and advanced practice providers prescribe Mounjaro off-label for obesity because the SURPASS-2 trial (N=1,879, published in NEJM 2021) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.46 percentage points and body weight by 12.4 kg compared with semaglutide 1 mg, which reduced HbA1c by 0.86 percentage points and body weight by 6.2 kg over 40 weeks [3]. That magnitude of glycemic and weight reduction is difficult to match with older oral agents. Delaware's obesity prevalence sits near 32% of adults per CDC Behavioral Risk Factor Surveillance data [4], giving clinicians a large population with legitimate medical need.

Tirzepatide's dual-receptor mechanism distinguishes it from single-agonist GLP-1 drugs. GIP receptor activation amplifies insulin secretion and may reduce the nausea burden common with GLP-1 monotherapy [5]. That tolerability profile matters for adherence in a real-world telehealth setting.

How Telehealth Prescribing Works in Delaware

Delaware permits telehealth prescribing of non-controlled medications, which includes tirzepatide. A prescriber licensed in Delaware may conduct a synchronous video visit, review your medical history and recent labs, and send an electronic prescription to a Delaware-licensed pharmacy or a mail-order pharmacy licensed to ship into the state. No in-person visit is required by Delaware law for this drug class [6].

The typical telehealth workflow runs as follows. First, you complete an online intake form covering current medications, diagnoses, prior weight-loss interventions, and any contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Second, a licensed Delaware prescriber reviews the intake, orders any outstanding labs, and schedules a video consult (often same-day or next-day). Third, the prescriber submits the prescription and, if needed, initiates a prior authorization request to your insurer. Fourth, the pharmacy ships the medication, typically arriving within 2 to 5 business days after the prescription clears.

Platforms operating under Delaware's telehealth framework must hold a valid Delaware prescriber license or employ one. When evaluating a platform, confirm the prescriber's Delaware license number is visible on the consent documentation before you pay.

Which Delaware Providers Can Prescribe Mounjaro

Physicians (MD, DO), nurse practitioners (NP), and physician assistants (PA) licensed by the Delaware Division of Professional Regulation may prescribe tirzepatide [7]. Delaware NPs with full practice authority do not require physician oversight to prescribe non-controlled medications, making them widely available through telehealth platforms. PAs in Delaware prescribe under a written agreement with a supervising physician, but that agreement does not need to list each drug by name for non-controlled substances.

Endocrinologists, primary care physicians, and obesity medicine specialists are the most common prescribers. Board certification in obesity medicine through the American Board of Obesity Medicine is not legally required but signals specific training in weight pharmacotherapy. Delaware has active obesity medicine practitioners affiliated with Christiana Care Health System and Bayhealth Medical Center, both of which offer outpatient metabolic health programs.

Labs Required Before Starting Mounjaro in Delaware

Most Delaware prescribers and all major telehealth platforms require a baseline lab panel before the first prescription is written. Comprehensive metabolic panel results must be recent, typically within 90 days. HbA1c confirms the presence or absence of type 2 diabetes and determines whether a diabetes indication or an off-label obesity indication applies. Fasting lipid panel, TSH, and a complete blood count round out the standard pre-treatment picture [8].

A urinalysis with microalbumin is often ordered when diabetes is already diagnosed, because tirzepatide's renal-protective signals noted in SURPASS-CRST may influence prescribing decisions for patients with early diabetic nephropathy [9]. Blood pressure measurement (self-reported or from a recent clinical visit) is also collected, since GLP-1 agonists produce modest systolic blood pressure reductions averaging 2 to 4 mmHg in trial data [10].

Some platforms accept labs drawn at a local Quest Diagnostics or LabCorp draw site in Delaware without a separate physician order, using a standing lab requisition the telehealth provider sends directly. Delaware has over 20 Quest and LabCorp patient service centers, so access is straightforward for most residents. Results typically return in 24 to 48 hours.

Absolute contraindications the lab review screens for include severe renal impairment (eGFR <15 mL/min/1.73m²) and active pancreatitis suggested by elevated lipase. The Mounjaro prescribing information advises caution in patients with a history of pancreatitis [2].

Delaware Insurance Coverage and Prior Authorization

Delaware Medicaid covers Mounjaro for the type 2 diabetes indication with prior authorization. The prior authorization package typically requires documentation of an HbA1c of 7% or above, confirmation of a type 2 diabetes diagnosis (ICD-10 code E11.x), evidence that the patient has tried at least one first-line agent such as metformin, and a letter of medical necessity from the prescriber [11].

Commercial insurance coverage varies by plan. The American Diabetes Association 2024 Standards of Care state: "For adults with type 2 diabetes, a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist is recommended for patients who need additional glucose lowering or cardiovascular and renal risk reduction" [12]. That language gives prescribers strong guideline support when writing a letter of medical necessity.

Off-label prior authorization for obesity without a diabetes diagnosis is harder to obtain on most Delaware commercial plans, because Mounjaro is FDA-approved for diabetes while Zepbound (same molecule) is the on-label obesity indication. If your insurer covers Zepbound, your prescriber may opt to prescribe that instead. If coverage for both is unavailable, compounded tirzepatide through a 503A pharmacy is an alternative worth discussing with your provider.

503A Compounding Pharmacies and Tirzepatide in Delaware

A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients pursuant to a valid prescription. Delaware-licensed 503A pharmacies may compound tirzepatide when a prescriber documents a specific patient need that the commercially available product cannot address, such as a documented shortage or a required dose not available in a commercial pen [13].

The FDA placed tirzepatide on the drug shortage list in 2023 and 2024, which expanded legal access to compounded versions. As of mid-2025, Lilly has indicated that certain Mounjaro dose strengths are back in supply, and the FDA removed tirzepatide injections from the shortage list in early 2025 [14]. Delaware prescribers should confirm current shortage status before routing a patient to a 503A compounder, as prescribing compounded tirzepatide outside an active shortage may raise regulatory and payer concerns.

When tirzepatide is legally available from a 503A pharmacy, the cost may range from $250 to $450 per month depending on dose, compared with the list price of approximately $1,050 per month for brand Mounjaro without insurance. Patients should verify that the 503A pharmacy holds an active Delaware Board of Pharmacy license or is licensed to ship into Delaware from another state.

The Step-by-Step Process to Get Mounjaro in Delaware

The path from decision to first injection breaks into five distinct steps for most Delaware patients.

Step 1: Confirm eligibility. You need a BMI of 27 or above with a weight-related condition (hypertension, dyslipidemia, sleep apnea, type 2 diabetes, or cardiovascular disease), or a BMI of 30 or above without a comorbidity, to meet widely used clinical criteria based on the 2023 American Heart Association obesity guideline [15]. An HbA1c at or above 6.5% independently qualifies you for the diabetes indication.

Step 2: Get labs. Order or locate a recent comprehensive metabolic panel, HbA1c, fasting lipid panel, and TSH. If you have had these drawn in the past 90 days, most telehealth platforms accept those results. Delaware Quest and LabCorp locations accept direct lab requisitions from participating telehealth platforms.

Step 3: Complete a telehealth consult. Choose a platform with a Delaware-licensed prescriber. The video consult typically runs 15 to 30 minutes. The prescriber reviews your labs, medical history, and goals, then either approves the prescription or requests additional information.

Step 4: Manage insurance or pharmacy options. If you have insurance, the prescriber's team submits prior authorization. Approval takes 3 to 14 business days. If you are self-pay, the prescription goes to a retail or mail-order pharmacy. GoodRx and manufacturer savings cards (Lilly's Mounjaro savings card caps out-of-pocket cost at $25 per month for eligible commercially insured patients) can reduce cost substantially [16].

Step 5: Begin the titration schedule. Mounjaro starts at 2.5 mg once weekly for 4 weeks, then increases to 5 mg once weekly. Subsequent titrations in 2.5 mg increments occur no faster than every 4 weeks, up to a maximum of 15 mg weekly per the FDA label [2]. Slower titration is appropriate for patients with significant gastrointestinal side effects.

What to Expect Clinically After Starting Mounjaro

The SURPASS-1 trial (N=478) demonstrated that tirzepatide 15 mg monotherapy reduced HbA1c by 2.07 percentage points from a baseline of 7.9% over 40 weeks, with 92% of participants achieving an HbA1c below 7% [17]. Nausea was the most common adverse event, reported in 12% to 18% of tirzepatide-treated participants across doses, compared with 6% on placebo. Most nausea was mild to moderate and occurred during dose escalation.

Weight loss data from the SURMOUNT-1 trial (N=2,539), which studied tirzepatide specifically for obesity, showed mean body weight reductions of 20.9% at the 15 mg dose over 72 weeks versus 3.1% on placebo [18]. The 5 mg and 10 mg doses produced 15.0% and 19.5% reductions respectively.

Common side effects Delaware patients should anticipate include nausea, diarrhea, constipation, vomiting, and injection-site reactions. Eating smaller meals, avoiding high-fat foods during the first weeks of therapy, and taking the injection on a day when activity is lighter can reduce GI burden. Hypoglycemia is uncommon in non-diabetic patients but may occur in type 2 diabetes patients also taking a sulfonylurea or insulin; dose reduction of the concomitant agent is typically required [2].

Delaware prescribers doing follow-up via telehealth typically schedule a 4-week check-in to assess tolerability before advancing the dose, then 8 to 12-week intervals once the patient is on a stable dose.

Transferring a Mounjaro Prescription to Delaware

If you started Mounjaro in another state and have relocated to Delaware, you have several straightforward options. A pharmacy-to-pharmacy transfer is legal for non-controlled medications in Delaware; call your current pharmacy and request a transfer to a Delaware location or a mail-order pharmacy licensed in Delaware. The receiving pharmacist handles the transfer directly.

If you need a refill authorization from the original prescriber and that prescriber is no longer available, a Delaware-licensed telehealth provider can conduct a new consult, review your medication history, and write a new prescription. Most platforms treat this as a standard new-patient consult. Bring documentation of your original diagnosis, previous dose, and any prior authorization approval letters, as these simplify the new PA process significantly if insurance coverage is involved.

Monitoring and Long-Term Management in Delaware

After the initial titration period, ongoing Mounjaro therapy requires periodic lab monitoring. HbA1c every 3 months during the first year is standard for the diabetes indication, dropping to every 6 months once targets are stable [12]. Renal function (creatinine, eGFR) and a lipid panel annually are reasonable for most patients. Blood pressure monitoring at home is low-cost and clinically informative given tirzepatide's modest antihypertensive effect.

Delaware telehealth platforms typically handle monitoring through asynchronous lab review. You draw labs at a local site, results transmit to the platform, and a provider reviews and messages recommendations through the patient portal. This avoids the need for repeated video visits once treatment is established.

Weight plateaus typically appear around 36 to 48 weeks on a fixed dose. SURMOUNT-4 data showed that patients who discontinued tirzepatide after 36 weeks of treatment regained, on average, about two-thirds of their lost weight within 88 weeks, confirming that tirzepatide manages rather than cures obesity [19]. Delaware providers generally frame Mounjaro as long-term therapy, not a short course, which affects insurance continuation criteria and patient expectations from the start of treatment.

The Endocrine Society's 2023 clinical practice guideline for pharmacological management of obesity states: "We recommend offering pharmacotherapy as an adjunct to lifestyle interventions for adults with obesity or overweight with weight-related complications" [20]. That recommendation applies directly to how Delaware providers position Mounjaro within a broader care plan that includes nutrition counseling and physical activity guidance.